Why the study?
Sustained fetal tachycardias carry a high risk of mortality and morbidity, but consensus has yet to be reached regarding their optimal management.
Design
Narrative review
Authors
Loading...
Fetal tachyarrhythmia management lacks consensus; review extends medication data but leaves standardization open pending prospective trials.
This narrative review suggests sotalol as first-line for fetal atrial flutter and flecainide for fetal SVT, particularly in hydropic fetuses, while emphasizing careful maternal-fetal evaluation.
Gozar et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: